By using ibrutinib, an inhibitor of the RTK BTK, it has been demonstrated that concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in AML through the inhibition of autophagy [52]. The gene discussed is FLT3; the disease is acute myeloid leukemia.